Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GZ17-6.02 Monotherapy and Combination with Capecitabine in Advanced Solid Tumors and Lymphoma
NCT03775525Phase 1Unknown
- Sponsor
- Genzada Pharmaceuticals USA Inc.
- Start
- Mar 2019
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of gz17-6.02 in solid tumor, lymphoma, Hormone-Receptor-Positive Breast Cancer and 1 more (3 arms), sponsored by Genzada Pharmaceuticals USA Inc. Primary endpoints: Maximum Tolerated Dose at 18 months, Recommended Phase 2 Dose at 18 months and 1 more. Status: unknown.
02
Drugs
gz17-6.02
03
Conditions
solid tumorlymphomaHormone-Receptor-Positive Breast Cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03775525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03775525.